ATE183196T1 - Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen - Google Patents

Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen

Info

Publication number
ATE183196T1
ATE183196T1 AT94902266T AT94902266T ATE183196T1 AT E183196 T1 ATE183196 T1 AT E183196T1 AT 94902266 T AT94902266 T AT 94902266T AT 94902266 T AT94902266 T AT 94902266T AT E183196 T1 ATE183196 T1 AT E183196T1
Authority
AT
Austria
Prior art keywords
fibronectin
collagen
binding proteins
peptide inhibitors
related collagen
Prior art date
Application number
AT94902266T
Other languages
English (en)
Inventor
David D Roberts
Henry C Krutzch
John M Sipes
Neng-Hua Guo
Eric Negre
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE183196T1 publication Critical patent/ATE183196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94902266T 1992-11-10 1993-11-09 Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen ATE183196T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/973,235 US5491130A (en) 1992-11-10 1992-11-10 Peptide inhibitors of fibronectin and related collagen-binding proteins

Publications (1)

Publication Number Publication Date
ATE183196T1 true ATE183196T1 (de) 1999-08-15

Family

ID=25520653

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94902266T ATE183196T1 (de) 1992-11-10 1993-11-09 Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen

Country Status (8)

Country Link
US (2) US5491130A (de)
EP (1) EP0669937B1 (de)
JP (2) JP3789931B2 (de)
AT (1) ATE183196T1 (de)
AU (1) AU683234B2 (de)
CA (1) CA2148383A1 (de)
DE (1) DE69326016T2 (de)
WO (1) WO1994011395A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2157927C (en) * 1993-03-12 1999-03-30 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein produc ts
JP3192067B2 (ja) * 1995-10-09 2001-07-23 科学技術振興事業団 ペプチドとコラーゲン収縮阻害剤
US6288214B1 (en) 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US20060025348A1 (en) * 1997-05-28 2006-02-02 Pilon Aprile L Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20020169108A1 (en) * 1997-05-28 2002-11-14 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
GB9714276D0 (en) 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
US6716963B1 (en) * 1998-05-22 2004-04-06 Abbott Laboratories Peptide antiangiogenic drugs
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
GB9903408D0 (en) * 1999-02-15 1999-04-07 Oxford Biomedica Ltd Peptides
WO2000063236A2 (en) * 1999-04-16 2000-10-26 Children's Medical Center Corporation Adhesion modulatory peptides and methods for use
CN1301723A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——纤维结合蛋白类型ii10和编码这种多肽的多核苷酸
EP1259548A1 (de) * 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antikörper gegen die ed-b domäne von fibronektin, konjugate die diesen antikörper enthalten, und deren verwendung zum nachweis und zur behandlung von angiogenese
US6309454B1 (en) 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
US20020197700A1 (en) * 2000-09-07 2002-12-26 Schering Ag Receptor of the EDb-fibronectin domains
EP1224943A1 (de) * 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin als Tumor Marker, detektiert durch auf Phagen exprimierte Antikörper
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
CN100385011C (zh) * 2003-05-09 2008-04-30 研究发展基金会 在膜蛋白中插入弗林蛋白酶切割位点及其用途
US20060024722A1 (en) * 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
EP2303308A4 (de) 2008-05-13 2012-11-07 Clarassance Inc Rekombinanter humaner cc10 und zusammensetzungen dafür zur verwendung bei der behandlung von nasaler rhinitis
WO2010017332A2 (en) * 2008-08-07 2010-02-11 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Radioprotectants targeting thrombospondin-1 and cd47
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
WO2011047065A1 (en) 2009-10-15 2011-04-21 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza
US10407665B2 (en) 2012-04-09 2019-09-10 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Methods for generation of pluripotent and multipotent cells
WO2014028862A1 (en) 2012-08-17 2014-02-20 Cornell University Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
CA2905418C (en) 2013-03-13 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
WO2015153732A2 (en) 2014-04-01 2015-10-08 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
FR3024364B1 (fr) 2014-07-31 2016-09-02 Neuronax Oligopeptides particuliers comme medicaments anti-angiogeniques
WO2016057702A2 (en) 2014-10-07 2016-04-14 Cornell University Methods for prognosing and preventing metastatic liver disease
US11971402B2 (en) 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1001013A4 (fr) * 1987-10-22 1989-06-13 Icp Internat Inst Of Cellular Derives de synergimycines de types a et b, procede pour leur preparation et utilisation de ceux-ci.
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
US5190918A (en) * 1990-02-22 1993-03-02 W. R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin and methods of use
US5357041A (en) * 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin

Also Published As

Publication number Publication date
AU5669594A (en) 1994-06-08
US5849701A (en) 1998-12-15
JP3789931B2 (ja) 2006-06-28
DE69326016T2 (de) 2000-04-13
EP0669937B1 (de) 1999-08-11
WO1994011395A1 (en) 1994-05-26
AU683234B2 (en) 1997-11-06
JP2006028195A (ja) 2006-02-02
CA2148383A1 (en) 1994-05-26
US5491130A (en) 1996-02-13
DE69326016D1 (de) 1999-09-16
JPH08510715A (ja) 1996-11-12
EP0669937A1 (de) 1995-09-06

Similar Documents

Publication Publication Date Title
DE69326016D1 (de) Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen
DE69231469D1 (de) Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen
DE69812630D1 (de) Integrinbindendes peptid und dessen verwendung
ATE411388T1 (de) Zell-durchlässige peptidinhibitoren des jnk- signaltransduktionsweges
ATE172743T1 (de) Nachweis von kollagenabbau -i(in vivo)
ATE380875T1 (de) Chimäre proteine zur vermeidung der komplementaktivierung
ES2061733T3 (es) Nuevos derivados peptidicos inhibidores de la agregacion de plaquetas.
DE59609235D1 (de) Verwendung von aerogelen in der landwirtschaft
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
DK0835447T3 (da) Peptider og sammensætninger, der modulerer apoptose
ATE216400T1 (de) Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle
ATE320488T1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
RU94036776A (ru) Домен ингибитора протеазы, днк, вектор, клетка, способ получения ингибитора протеазы, фармацевтическая композиция, применение домена ингибитора протеазы
ATE193022T1 (de) Heparin-und sulfatid-bindende peptide vom typ 1 der wiederkehrenden sequenzen vom menschlichen thrombospondin
WO2000048625A3 (en) Inhibitors for use in hemostasis and immune function
ES2058479T3 (es) Compuestos peptidicos.
ATE191223T1 (de) Verwendung von zelladhäsions-peptiden zur modifikation des haftungsvermögens eukaryontischer zellen untereinander
DE69919684D1 (de) Verwendung von isolierten domänen des type-iv-kollagens zur änderung der zell- und gewebewechselwirkung
MX9304070A (es) Piperidilamidas, piperidilsulfonamidas y piperidilsulfoxamidas novedosas como inhibidores de la biosintesis del colesterol.
ATE226591T1 (de) Oligopeptide hergeleitet von fragmenten des c- reaktiven proteins
DE59406092D1 (de) Verwendung von carboxylgruppen enthaltenden umsetzungsprodukten von proteinen oder proteinhydrolysaten in wasch- und reinigungsmitteln
NO933423D0 (no) Modifisert blodplate-faktor-4
Daramola et al. Detection of fibronectin expression by human endothelial cells using a enzyme-linked immunosorbent assay (ELISA): enzymatic degradation by activated plasminogen
ES2109487T3 (es) Analogos de tetrapeptidos parcialmente modificados y retroinvertidos de fragmentos de proteina c-reactiva.
MY106261A (en) Anti-inflammatory 1-heteroaryl oxindole-3-carboxamides.